Overview

Safety Study of the Combination of Panitumumab, Irinotecan and Everolimus in the Treatment of Advanced Colorectal Cancer

Status:
Completed
Trial end date:
2017-06-01
Target enrollment:
Participant gender:
Summary
This study will assess the safety of panitumumab, irinotecan and everolimus when given in combination to treat advanced colorectal cancer
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
The Queen Elizabeth Hospital
Collaborators:
Amgen
Novartis
Treatments:
Antibodies, Monoclonal
Camptothecin
Everolimus
Irinotecan
Panitumumab
Sirolimus